Discovery of pyrrolo[2,3-d]pyrimidin-4-ones as corticotropin-releasing factor 1 receptor antagonists with a carbonyl-based hydrogen bonding acceptor

被引:6
作者
Aso, Kazuyoshi [1 ]
Kobayashi, Katsumi [1 ]
Mochizuki, Michiyo [1 ]
Kanzaki, Naoyuki [2 ]
Sako, Yuu [3 ]
Yano, Takahiko [3 ]
机构
[1] Takeda Pharmaceut Co Ltd, Div Pharmaceut Res, Med Chem Res Labs, Yodogawa Ku, Osaka 5328686, Japan
[2] Takeda Pharmaceut Co Ltd, Div Pharmaceut Res, Discovery Res Ctr, Yodogawa Ku, Osaka 5328686, Japan
[3] Takeda Pharmaceut Co Ltd, Div Pharmaceut Res, Pharmaceut Res Labs, Yodogawa Ku, Osaka 5328686, Japan
关键词
Corticotropin-releasing factor; CRF1; antagonist; Pyrrolo[2,3-d]pyrimidin-4-one; Hydrogen bonding acceptor; PLACEBO-CONTROLLED TRIAL; THYMIDYLATE SYNTHASE; MOLECULAR-PROPERTIES; MAJOR DEPRESSION; STRESS-RESPONSE; CRF RECEPTOR; ANXIETY; EFFICACY; LACKING; SAFETY;
D O I
10.1016/j.bmcl.2011.02.086
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A new class of pyrrolo[2,3-d]pyrimidin-4-one corticotropin-releasing factor 1 (CRF1) receptor antagonists has been designed and synthesized. In general, reported CRF1 receptor antagonists possess a sp(2)-nitrogen atom as hydrogen bonding acceptor (HBA) on their core scaffolds. We proposed to use a carbonyl group of pyrrolo[2,3-d]pyrimidin-4-one derivatives as a replacement for the sp(2)-nitrogen atom as HBA in classical CRF1 receptor antagonists. As a result, several pyrrolo[2,3-d]pyrimidin-4-one derivatives showed CRF1 receptor binding affinity with IC50 values in the submicromolar range. Ex vivo I-125-sauvagine binding studies showed that 2-(dipropylamino)-3,7-dimethyl-5-(2,4,6-trimethylphenyl)-3,7-dihydro-4H-pyrrolo [2,3-d]pyrimidin-4-one (16b) (30 mg/kg, po) was able to penetrate into the brain and inhibit radioligand binding to CRF1 receptors (frontal cortex, olfactory bulb, and pituitary) in mice. We identified pyrrolo[2,3-d] pyrimidin-4-one derivatives as the first CRF1 antagonists with a carbonyl-based HBA. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2365 / 2371
页数:7
相关论文
共 26 条
[1]  
ASO K, 1995, CHEM PHARM BULL, V43, P256
[2]   Pyrrolo[2,3-d]pyrimidine thymidylate synthase inhibitors:: Design and synthesis of one-carbon bridge derivatives [J].
Aso, K ;
Imai, Y ;
Yukishige, K ;
Ootsu, K ;
Akimoto, H .
CHEMICAL & PHARMACEUTICAL BULLETIN, 2001, 49 (10) :1280-1287
[3]   A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression [J].
Binneman, Brendon ;
Feltner, Douglas ;
Kolluri, Sheela ;
Shi, Yuanjun ;
Qiu, Ruolun ;
Stiger, Thomas .
AMERICAN JOURNAL OF PSYCHIATRY, 2008, 165 (05) :617-620
[4]   MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE COMPARATOR AND PLACEBO-CONTROLLED TRIAL OF A CORTICOTROPIN-RELEASING FACTOR RECEPTOR-1 ANTAGONIST IN GENERALIZED ANXIETY DISORDER [J].
Coric, Vladimir ;
Feldman, Howard H. ;
Oren, Dan A. ;
Shekhar, Anantha ;
Pultz, Joseph ;
Dockens, Randy C. ;
Wu, Xiaoling ;
Gentile, Kimberly A. ;
Huang, Shu-Pang ;
Emison, Eileen ;
Delmonte, Terrye ;
D'Souza, Bernadette B. ;
Zimbroff, Daniel L. ;
Grebb, Jack A. ;
Goddard, Andrew W. ;
Stock, Elyse G. .
DEPRESSION AND ANXIETY, 2010, 27 (05) :417-425
[5]   Recent Advances in Corticotropin-Releasing Factor Receptor Antagonists [J].
Dzierba, Carolyn D. ;
Hartz, Richard A. ;
Bronson, Joanne J. .
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 43, 2008, 43 :3-23
[6]   3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl-imidazo[1,2-b]pyridazine:: A novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism [J].
Gehlert, Donald R. ;
Cippitelli, Andrea ;
Thorsell, Annika ;
Le, Anh Dzung ;
Hipskind, Philip A. ;
Hamdouchi, Chafiq ;
Lu, Jianliang ;
Hembre, Erik J. ;
Cramer, Jeffrey ;
Song, Min ;
McKinzie, David ;
Morin, Michelle ;
Ciccocioppo, Roberto ;
Heilig, Markus .
JOURNAL OF NEUROSCIENCE, 2007, 27 (10) :2718-2726
[7]  
Grigoriadis Dimitri E., 2001, Current Medicinal Chemistry - Central Nervous System Agents, V1, P63, DOI 10.2174/1568015013358734
[8]   4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A):: A potent and selective corticotrophin-releasing factor1 receptor antagonist.: I.: Biochemical and pharmacological characterization [J].
Gully, D ;
Geslin, M ;
Serva, L ;
Fontaine, E ;
Roger, P ;
Lair, C ;
Darre, V ;
Marcy, C ;
Rouby, PE ;
Simiand, J ;
Guitard, J ;
Gout, G ;
Steinberg, R ;
Rodier, D ;
Griebel, G ;
Soubrie, P ;
Pascal, M ;
Pruss, R ;
Scatton, B ;
Maffrand, JP ;
Le Fur, G .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 301 (01) :322-332
[9]   Structure-brain exposure relationships [J].
Hitchcock, Stephen A. ;
Pennington, Lewis D. .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (26) :7559-7583
[10]   The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety [J].
Holsboer, F .
JOURNAL OF PSYCHIATRIC RESEARCH, 1999, 33 (03) :181-214